Commitments and Contingencies - Additional Details (Details) $ in Millions					2 Months Ended	12 Months Ended
	Nov. 21, 2018 ILS (₪)	Jun. 28, 2017 USD ($) product defendant	Jun. 28, 2017 ILS (₪) product defendant	Dec. 27, 2013 defendant	Nov. 30, 2011 application	Dec. 31, 2018 USD ($) case dozens $ / ₪	Dec. 31, 2017 USD ($) case	Dec. 31, 2016 USD ($)	Feb. 22, 2019 product plaintiff case defendant	Feb. 14, 2019 defendant	Feb. 06, 2019 product case defendant	Jan. 31, 2019 product case defendant	Nov. 15, 2018 product case	Oct. 29, 2018 product case defendant	Apr. 20, 2018 product case	Feb. 16, 2018 case defendant	Feb. 13, 2018 product case defendant	Jan. 26, 2018 product plaintiff case complaint	Jan. 16, 2018 product defendant	Nov. 01, 2017 defendant	Jun. 21, 2017 product individual	Dec. 28, 2013 product manufacturer supermarket	Dec. 31, 2011 product manufacturer
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2019 | $						$ 39.3
2020 | $						32.0
2021 | $						24.9
2022 | $						16.3
2023 | $						10.3
Thereafter | $						33.0
Loss Contingencies [Line Items]
Rent expense under all leases | $						51.2	$ 50.9	$ 53.0
Purchase obligation | $						$ 758.3
Number of dozens of other drugs | dozens						2
Number of manufacturers | manufacturer																							27
Number of generic prescription pharmaceuticals | product																		6			6		15
Number of individuals | individual																					11
Number of plaintiff groups | plaintiff																		2
Number of complaints | complaint																		2
Number of cases																		2
Number of overlapped cases																		2
Number of drugs | product																							2
Price-Fixing Lawsuit, Supermarket Chains
Loss Contingencies [Line Items]
Number of manufacturers | manufacturer																						35
Number of supermarket chains | supermarket																						3
Number of generic prescription pharmaceuticals | product																						31
Price-fixing Lawsuit, Managed Care Organization
Loss Contingencies [Line Items]
Number of manufacturers | manufacturer																						27
Number of generic prescription pharmaceuticals | product																						17
Price-fixing Lawsuit, Health Insurance Carrier
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product																						30
Number of defendants | defendant				30
Carmignac Gestion, S.A. v. Perrigo Company plc, et al.
Loss Contingencies [Line Items]
Number of co-defendants | defendant																				3
Manning & Napier Advisors, LLC v. Perrigo Company plc, et al.
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product																			6
Number of co-defendants | defendant																			3
Harel Insurance Company, LTD., et al. v. Perrigo Company plc, et al.
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product																	6
Number of co-defendants | defendant																	2
Number of opt out cases																	4
First Manhattan Co. v. Perrigo Company plc, et al. [Member]
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals																6
Number of co-defendants | defendant																3
Number of opt out cases																5
TIAA-CREF Investment Management, LLC., et al. v. Perrigo Company plc, et al.
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product															6
Number of opt out cases															6
Nationwide Mutual Funds, et al. v. Perrigo Company plc, et al.
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product														6
Number of co-defendants | defendant														2
Number of opt out cases														7
WCM Alternative: Event-Drive Fund, et al. v. Perrigo Co., plc, et al.
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product													6
Number of opt out cases													8
Hudson Bay Master Fund Ltd., et al. v. Perrigo Co., plc, et al.
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals													6
Number of opt out cases													9
Schwab Capital Trust, et al. v. Perrigo Company plc, et al. | Subsequent Event
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product												6
Number of co-defendants | defendant												2
Number of opt out cases												10
OZ Master Fund, Ltd., et al. v. Perrigo Company plc, et al. | Subsequent Event
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product											6
Number of co-defendants | defendant											2
Number of opt out cases											11
Highfields Capital I LP, et al. v. Perrigo Company plc, et al. | Subsequent Event
Loss Contingencies [Line Items]
Number of co-defendants | defendant										2
Aberdeen Canada Funds - Global Equity Fund, et al. v. Perrigo Company plc, et al. | Subsequent Event
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product									6
Number of co-defendants | defendant									2
Number of other entities | plaintiff									30
Number of opt out cases									12
Cases Filed in Israel
Loss Contingencies [Line Items]
Number of cases							3
Number of cases dismissed						1	1
Number of cases stayed						1
Israel Elec. Corp. Employees' Educ. Fund v. Perrigo Company plc, et al.
Loss Contingencies [Line Items]
Number of generic prescription pharmaceuticals | product		6	6
Foreign currency exchange rate, remeasurement | $ / ₪						0.28
Number of current or former directors and officers | defendant		11	11
Preliminary class damages		$ 760.0	₪ 2,700,000,000
Eltroxin Class Action
Loss Contingencies [Line Items]
Number of applications filed | application					9
Number of applications dismissed | application					1
Number of applications consolidated | application					8
Loss Contingency, Damages Sought, Value per Patient | ₪	₪ 250